tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
US Market
APLS
Apellis Pharmaceuticals
Overview
Analyst Forecasts
AI Stock Analysis
Popular
Dividends
Earnings
Ownership
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

Apellis Pharmaceuticals (APLS) Stock News & Sentiment

Compare
884 Followers
Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation
Premium
Ratings
Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation
8d ago
APLS
Cautious Hold on Apellis Pharmaceuticals Amid Competitive Landscape and Promising Empaveli Prospects
Premium
Ratings
Cautious Hold on Apellis Pharmaceuticals Amid Competitive Landscape and Promising Empaveli Prospects
19d ago
APLS
Apellis Pharmaceuticals: Favorable Market Positioning and Strong Clinical Results Justify Buy Rating
Premium
Ratings
Apellis Pharmaceuticals: Favorable Market Positioning and Strong Clinical Results Justify Buy Rating
19d ago
APLS
Buy Rating for Apellis Pharmaceuticals Driven by Empaveli’s Market Potential and Efficacy in C3G Treatment
Premium
Ratings
Buy Rating for Apellis Pharmaceuticals Driven by Empaveli’s Market Potential and Efficacy in C3G Treatment
19d ago
APLS
Positive Long-term Outlook and Strategic Positioning Drive Buy Rating for Apellis Pharmaceuticals
Premium
Ratings
Positive Long-term Outlook and Strategic Positioning Drive Buy Rating for Apellis Pharmaceuticals
1M ago
APLS
Buy Rating for Apellis Pharmaceuticals Driven by Strategic Growth Initiatives and Strong Product Performance
Premium
Ratings
Buy Rating for Apellis Pharmaceuticals Driven by Strategic Growth Initiatives and Strong Product Performance
1M ago
APLS
Hold Rating for Apellis Pharmaceuticals Amidst Market Challenges and Moderate Growth Expectations
Premium
Ratings
Hold Rating for Apellis Pharmaceuticals Amidst Market Challenges and Moderate Growth Expectations
1M ago
APLS
More APLS News >

APLS News on the Web

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag
Zacks
Neutral
Deep Track Capital, LP's Strategic Acquisition of Geron Corp Shares
GuruFocus News
Neutral
EcoR1 Capital, LLC Increases Stake in Zymeworks Inc
GuruFocus News
Neutral
Deep Track Capital, LP Acquires Significant Stake in Dianthus Therapeutics Inc
GuruFocus News
Neutral
Evercore ISI Remains a Buy on Apellis Pharmaceuticals (APLS)
TipRanks News
Neutral
EcoR1 Capital, LLC's Strategic Acquisition of Zymeworks Inc Shares
GuruFocus News
Neutral
Morgan Stanley says Fabhalta's label leaves opportunity for Apellis' Empaveli
The Fly
Neutral
Apellis Pharmaceuticals (APLS) Gets a Hold from Mizuho Securities
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
APLS
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.75 articles
News Sentiment
This Week50%
Sector Average62%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is APLS’s Media Buzz Sentiment?
1 articles about APLS were published this week. In an average week, 1.75 articles are published.
    What is APLS’s weekly average amount of articles?
    In an average week, 1.75 articles about APLS are published.
      What is APLS’s News Sentiment?
      50% of articles about APLS were positive this week, compared to its sector average of 62%.
        Healthcare Stocks that are Trending in the News
        RYTMRhythm Pharmaceuticals
        WBAWalgreens Boots Alliance
        BRKRBruker
        UNHUnitedHealth
        SLPSimulations Plus
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing